Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders

Inclusion criteria

• Men and women over 60 years of age.
• DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.
• Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.
• Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both
• Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.
• Having voluntarily and informedly agreed to participate in the study (signed written consent).
• Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).
• Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.
• Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.
• Subjects covered by a social security scheme.

Exclusion criteria

• Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.
• Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).
• Major hearing or visual impairments.
• History of premorbid intellectual disability.
• Patients under guardianship, conservatorship, or legal protection.
• Patients who have already used the Lilia app
• Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.
• Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.